Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Zentalis Pharmaceuticals, Inc. (ZNTL)

Zentalis Pharmaceuticals Adds Shannon Campbell as Director, Board Expands to Seven

Neutral Impact 2 of 5 leadership Written later

Zentalis Pharmaceuticals increased its Board from six to seven directors and appointed Shannon Campbell as a Class I director effective May 22, 2026. She also joined the Compensation Committee and receives standard non-employee director pay and equity grants.

Key points

  • Board size increased from six to seven directors, effective May 22, 2026.
  • Campbell's initial term runs to the 2027 Annual Meeting of Stockholders.
  • Annual retainer of $45,000 for Board service, plus $7,500 for Compensation Committee membership.
  • Initial RSU grant of 114,200 shares on May 26, 2026, vesting in thirds over three years.

The filing

CompanyZentalis Pharmaceuticals, Inc. (ZNTL)
Form8-K, current report
Filed with the SECMay 27, 2026, 4:07 PM ET
Accession number0001725160-26-000049

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.